Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy

NCT00919711 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

870

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: Actonel®
DRUG: Denosumab

Sponsor

Amgen